A Study of IBI351 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 16, 2023

Primary Completion Date

October 16, 2023

Study Completion Date

October 16, 2023

Conditions

Healthy Subjects

Interventions

DRUG

IBI351

IBI351 is administered orally

DRUG

Esomeprazole

Esomeprazole is administered orally

Trial Locations (1)

the First Affiliated Hospital of Suzhou University, Suzhou

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY